The FDA has granted the CDK4/6 inhibitor abemaciclib a breakthrough therapy designation as monotherapy for heavily pretreated patients with refractory hormone-receptor-positive advanced breast cancer. http://www.onclive.com/web-exclusives/fda-grants-abemaciclib-breakthrough-status-for-refractory-breast-cancer
Best Integrative, Alternative, Complementary Cancer Center, Manila
Finding the best treatment for cancer. Complementary and alternative cancer therapies that are scientifically proven.
Leave a comment